Table 2.

Baseline and On-Trial Hormone Levels by Treatment Group

Hormone	Placebo group (N=104)	Estradiol group (N=90)	P-value*
	Mean (SD)	Mean (SD)
Estradiol (pg/ml)
Baseline	19.1 ( 8.4)	20.3 ( 12.2)	0.53
On-trial	17.2 ( 12.0)	61.5 (16.2 )	<0.001
Estrone (pg/ml)
Baseline	44.3 ( 16.5)	48.9 ( 44.6)	0.02
On-trial	46.2 ( 39.2)	296.6 ( 198.1)	<0.001
Bioavailable Estradiol (pg/ml)
Baseline	14.1 ( 4.7)	16.8 ( 14.2)	0.08
On-trial	14.7 ( 6.7)	39.2 ( 20.2)	<0.001
Free Estradiol (pg/ml)
Baseline	0.6 ( 0.2)	0.7 ( 0.6)	0.08
On-trial	0.6 ( 0.3)	1.5 ( 0.8)	<0.001
Testosterone (ng/dl)
Baseline	22.9 ( 9.5)	21.7 ( 10.4)	0.38
On-trial	22.6 ( 9.6)	23.3 ( 11.9)	0.46
DHEA (ng/ml)
Baseline	2.3 (1.5)	2.2 ( 1.4)	0.55
On-trial	2.1 ( 1.3)	1.9 ( 1.0)	0.02
Androstenedione (pg/ml)
Baseline	515.1 ( 221.3)	522.9 ( 247.7)	0.82
On-trial	508.4 ( 194.3)	515.7 ( 214.4)	0.64
Bioavailable testosterone (ng/ml)
Baseline	9.4 ( 4.5)	8.9 ( 4.9)	0.50
On-trial	9.1 ( 4.0)	7.1 ( 4.0)	<0.001
Free Testosterone (pg/ml)
Baseline	4.3 ( 2.0)	4.1 ( 2.3)	0.50
On-trial	4.1 ( 1.8)	3.2 ( 1.8)	<0.001
SHBG (nmol/l)
Baseline	35.2 ( 15.1)	36.4 ( 21.6)	0.64
On-trial	36.3 ( 19.3)	57.1 ( 27.3)	<0.001

^*P-value from independent t-test;

SHBG: Sex hormone-binding globulin; DHEA: Dehydroepiandrosterone